Chemiogram and syntetic lethality: a new horizon in individualized medicine for canine oncologic patient

• Grant number: 23/01778-7
• Support Opportunities: Regular Research Grants
• Start date: June 01, 2023
• End date: May 31, 2026
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Pathology
• Principal Investigator: Renee Laufer Amorim
• Grantee: Renee Laufer Amorim
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Associated researchers: Carlos Eduardo Fonseca Alves ; Cristina de Oliveira Massoco Salles Gomes ; Flávia Karina Delella ; Julia Maria Matera

Abstract

Cancer is a common disease between humans and companion animals, and dogs are considered good natural models, since they share the same environment as humans. In animals, it is estimated that one in four dogs will develop neoplasia throughout life, and those over 10 years of age have a 50% chance of developing cancer. The therapy of choice for cancer patients is surgery, which should or should not be associated with chemo and/or radiotherapy. However, the treatment of choice is not always adequate and sufficient to control the disease in animal with higher clinical staging or irresectable tumors. Individualized treatment is an option that has been increasing in human medicine, but not in veterinary oncology. For us to have that opportunity as a treatment option, studies are necessary, validating the ex vivo screening technique, as a first step for future clinical trial studies. The research project aims to standardize the ex vivo screening test for the most used chemotherapy and natural compounds, including the concept of synthetic lethality, with the future perspective of translational medicine for cancer patients. We have full institutional support, from researchers with experience in cell culture and drug sensitivity tests, and a partnership with private owned veterinary oncology clinics. (AU)